Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value.

Olchanski N, Hansen RN, Pope E, D'Cruz B, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, Schaecher K, Shaya FT, Neumann PJ, Sullivan SD.

Open Forum Infect Dis. 2018 Feb 7;5(3):ofy031. doi: 10.1093/ofid/ofy031. eCollection 2018 Mar. Review.

2.

Burden of Respiratory Syncytial Virus Hospitalizations in Canada.

Mitchell I, Defoy I, Grubb E.

Can Respir J. 2017;2017:4521302. doi: 10.1155/2017/4521302. Epub 2017 Nov 7.

3.

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.

Pavilack M, Clifford RA, Gonzales T, Kong AM, Wade S, McLaurin KK.

Infect Dis Ther. 2018 Mar;7(1):121-134. doi: 10.1007/s40121-017-0178-6. Epub 2017 Nov 17.

4.

Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis.

Rodriguez-Fernandez R, Tapia LI, Yang CF, Torres JP, Chavez-Bueno S, Garcia C, Jaramillo LM, Moore-Clingenpeel M, Jafri HS, Peeples ME, Piedra PA, Ramilo O, Mejias A.

J Infect Dis. 2017 Dec 27;217(1):24-34. doi: 10.1093/infdis/jix543.

PMID:
29045741
5.

Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic.

Chow JW, Chicella MF, Christensen AM, Moneymaker CS, Harrington J, Dice JE.

J Pediatr Pharmacol Ther. 2017 Sep-Oct;22(5):338-343. doi: 10.5863/1551-6776-22.5.338.

6.

Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.

Coates M, Brookes D, Kim YI, Allen H, Fordyce EAF, Meals EA, Colley T, Ciana CL, Parra GF, Sherbukhin V, Stockwell JA, Thomas JC, Hunt SF, Anderson-Dring L, Onions ST, Cass L, Murray PJ, Ito K, Strong P, DeVincenzo JP, Rapeport G.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00737-17. doi: 10.1128/AAC.00737-17. Print 2017 Sep.

7.

Respiratory syncytial virus infection activates IL-13-producing group 2 innate lymphoid cells through thymic stromal lymphopoietin.

Stier MT, Bloodworth MH, Toki S, Newcomb DC, Goleniewska K, Boyd KL, Quitalig M, Hotard AL, Moore ML, Hartert TV, Zhou B, McKenzie AN, Peebles RS Jr.

J Allergy Clin Immunol. 2016 Sep;138(3):814-824.e11. doi: 10.1016/j.jaci.2016.01.050. Epub 2016 Apr 9.

9.

Viral Specific Factors Contribute to Clinical Respiratory Syncytial Virus Disease Severity Differences in Infants.

Thompson TM, Roddam PL, Harrison LM, Aitken JA, DeVincenzo JP.

Clin Microbiol. 2015 Jun;4(3). pii: 206. Epub 2015 Jun 29.

10.

Vitamin D Levels Are Unrelated to the Severity of Respiratory Syncytial Virus Bronchiolitis Among Hospitalized Infants.

Beigelman A, Castro M, Schweiger TL, Wilson BS, Zheng J, Yin-DeClue H, Sajol G, Giri T, Sierra OL, Isaacson-Schmid M, Sumino K, Schechtman KB, Bacharier LB.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):182-8. doi: 10.1093/jpids/piu042. Epub 2014 Jun 5.

11.

Risk of urinary tract infection in infants and children with acute bronchiolitis.

Hendaus MA, Alhammadi AH, Khalifa MS, Muneer E, Chandra P.

Paediatr Child Health. 2015 Jun-Jul;20(5):e25-9.

12.

Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity.

Brown PM, Schneeberger DL, Piedimonte G.

Paediatr Respir Rev. 2015 Sep;16(4):232-40. doi: 10.1016/j.prrv.2015.05.005. Epub 2015 May 23. Review.

13.

Bordetella pertussis is an uncommon pathogen in children hospitalized with bronchiolitis during the winter season.

Piedra PA, Mansbach JM, Jewell AM, Thakar SD, Grant CC, Sullivan AF, Espinola JA, Camargo CA Jr.

Pediatr Infect Dis J. 2015 Jun;34(6):566-70. doi: 10.1097/INF.0000000000000596.

14.

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.

Ambrose CS, Chen X, Kumar VR.

Hum Vaccin Immunother. 2014;10(10):2785-8. doi: 10.4161/hv.32082. Epub 2014 Nov 21.

15.

Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis.

Beigelman A, Isaacson-Schmid M, Sajol G, Baty J, Rodriguez OM, Leege E, Lyons K, Schweiger TL, Zheng J, Schechtman KB, Castro M, Bacharier LB.

J Allergy Clin Immunol. 2015 May;135(5):1171-8.e1. doi: 10.1016/j.jaci.2014.10.001. Epub 2014 Nov 18.

16.

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis.

Pickles RJ, DeVincenzo JP.

J Pathol. 2015 Jan;235(2):266-76. doi: 10.1002/path.4462. Review.

17.

Perinatal and early childhood environmental factors influencing allergic asthma immunopathogenesis.

Gaffin JM, Kanchongkittiphon W, Phipatanakul W.

Int Immunopharmacol. 2014 Sep;22(1):21-30. doi: 10.1016/j.intimp.2014.06.005. Epub 2014 Jun 19. Review.

18.

Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.

Cagno V, Donalisio M, Civra A, Volante M, Veccelli E, Oreste P, Rusnati M, Lembo D.

Antimicrob Agents Chemother. 2014 Aug;58(8):4782-94. doi: 10.1128/AAC.02594-14. Epub 2014 Jun 9.

19.

Vitamin D-binding protein haplotype is associated with hospitalization for RSV bronchiolitis.

Randolph AG, Yip WK, Falkenstein-Hagander K, Weiss ST, Janssen R, Keisling S, Bont L.

Clin Exp Allergy. 2014 Feb;44(2):231-7. doi: 10.1111/cea.12247.

20.

Respiratory syncytial virus surveillance in the United States, 2007-2012: results from a national surveillance system.

McGuiness CB, Boron ML, Saunders B, Edelman L, Kumar VR, Rabon-Stith KM.

Pediatr Infect Dis J. 2014 Jun;33(6):589-94. doi: 10.1097/INF.0000000000000257.

Supplemental Content

Support Center